Literature DB >> 9447563

Determination of tolterodine and the 5-hydroxymethyl metabolite in plasma, serum and urine using gas chromatography-mass spectrometry.

L Palmér1, L Andersson, T Andersson, U Stenberg.   

Abstract

A specific and sensitive capillary gas chromatography-mass spectrometry assay for the determination of tolterodine and the 5-hydroxymethyl metabolite (Labcode DD 01) in plasma, serum and urine is described. Extraction of the analytes was performed with liquid/liquid or solid-phase extraction prior to derivatisation with a silyl reagent. The derivatives were quantified by selected ion monitoring mass spectrometry using deuterium-labelled internal standards. A single level calibration curve was utilised for quantification of plasma, serum and urine concentrations of tolterodine and DD 01. The accuracy (inter- and intra-day) for both analytes was within 87-110% in the range 0.5 and 50 ng ml-1 and precision was better than 90%. Overall, this method was shown to be reliable for pharmacokinetic assays of tolterodine and the metabolite DD 01 in samples from preclinical and clinical studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447563     DOI: 10.1016/s0731-7085(97)00023-x

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  10 in total

1.  Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.

Authors:  B Olsson; J Szamosi
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.

Authors:  N Brynne; C Svanström; A Aberg-Wistedt; B Hallén; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

3.  Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.

Authors:  N Brynne; C Forslund; B Hallén; L L Gustafsson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

4.  Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.

Authors:  N Brynne; Y Böttiger; B Hallén; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

5.  Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder.

Authors:  B Olsson; J Szamosi
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  A New Rapid and Sensitive Stability-Indicating UPLC Assay Method for Tolterodine Tartrate: Application in Pharmaceuticals, Human Plasma and Urine Samples.

Authors:  Ramesh Yanamandra; Chandra Sekhar Vadla; Umamaheshwar Puppala; Balaram Patro; Yellajyosula L N Murthy; Parimi Atchuta Ramaiah
Journal:  Sci Pharm       Date:  2011-12-05

8.  A validated LC-MS/MS method for the determination of tolterodine and its metabolite in rat plasma and application to pharmacokinetic study.

Authors:  Rihana Parveen Shaik; Srinivasa Babu Puttagunta; Chandrasekhar Bannoth Kothapalli; Bahlul Zayed Sh Awen; B R Challa
Journal:  J Pharm Anal       Date:  2013-05-24

Review 9.  Role of fesoterodine in the treatment of overactive bladder.

Authors:  Kylie J Mansfield
Journal:  Open Access J Urol       Date:  2009-12-17

10.  Isolation, Identification, and Characterisation of Degradation Products and the Development and Validation of a Stability-Indicating Method for the Estimation of Impurities in the Tolterodine Tartrate Formulation.

Authors:  Lakkireddy Prakash; Malipeddi Himaja; Rudraraju Vasudev
Journal:  Sci Pharm       Date:  2014-09-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.